The global Hepatitis B Treatment Market size was estimated at USD USD 548.84 Mn in 2021, growing at a CAGR of 10.2% during the forecast period 2021-2027. Hepatitis-B is also known serum hepatitis which is an infectious disease of the liver caused by Hepatitis-B virus (HBV). Hepatitis B is classified into two types namely, acute and chronic. In this condition, the virus interferes with the hepatocytes and the liver became inflamed. Hepatitis-B is commonly caused through parenteral contacts such as blood, body fluids, and sexual intercourse. Hepatitis-B virus is unable to cross the skin or mucous membrane. People with Lymph proliferative disease, Acquired Immuno Deficiency Syndrome (AIDS), and people treated with immunosuppressant drugs and haemodialysis patients are easily develop an infection with Hepatitis-B Virus. The symptoms of the Hepatitis B do not develop until after a few weeks of exposure. The severity in Hepatitis may cause the cirrhosis, liver failure, and hepatocellular carcinoma (HCC). A vaccine is commonly administered to protect people from the infection. Hepatitis B can be prevented by administering the hepatitis B vaccine to newborn babies, avoiding promiscuity and not having multiple sexual partners, and avoiding sharing of injections and razors can also prevent the Hepatitis B infection.

Geographically, hepatitis B treatment market is in growing stage, as various government organizations are initiating awareness programs to prevent the hepatitis B infection. Increase in the prevalence of hepatitis B infection and liver cirrhosis might fuel the hepatitis B treatment market. According to the World Health Organization, there are currently 240 million chronic carriers of hepatitis B virus in which approximately 15–25% of carriers will develop cirrhosis, hepatocellular carcinoma (HCC), or liver decompensation, and 780,000 will die each year as a result of their infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their share in global hepatitis b treatment market. For instance, in September 2013, Roche and Inovio Pharmaceuticals collaborated on research, development, and commercialization of Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting hepatitis B and prostate cancer. Similarly, in July 2015, Benitec Biopharma and Biomics Biotechnologies are announced that Benitec has acquired the full rights to the pre-clinical ddRNAi-based hepatitis B (HBV) therapeutic program, Hepbarna, which was previously under development as a joint venture between the two companies. In addition, in October 2010, U.S. Food and Drug Administration approved the Baraclude (Entecavir) for hepatitis B treatment with the decompensated liver disease in adults manufactured by Bristol Myers Squibb. Moreover, various drugs for the hepatitis B treatment in the pipeline also expected to propel the hepatitis B treatment market over the forecast period.


Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084


Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX